Tags

Type your tag names separated by a space and hit enter

Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up.
Ophthalmic Surg Lasers. 2000 Jul-Aug; 31(4):301-7.OS

Abstract

PURPOSE

To evaluate and compare the long term safety and efficacy of low-dose intraoperative application of mitomycin-C (0.02%) with conjunctival autograft in primary pterygium surgery.

PATIENTS AND METHODS

Of 37 consecutive patients 41 eyes with primary pterygium underwent pterygium excision with either intraoperative mitomycin-C (0.02%) (Group I) or conjunctival autografts (Group II) at random. Mitomycin-C (0.2 mg/mL) was applied for 2.5 minutes on the scleral bed under the conjunctiva. Conjunctival autograft was obtained from upper temporal limbus and secured with 10-0 monofilament nylon. The follow-up period ranged from 14 to 54 months (mean 36 months) for mitomycin-C group and 13 to 58 months (mean 38 months) for conjunctival autograft group.

RESULTS

Twenty-one eyes underwent pterygium excision with intraoperative mitomycin-C (0.02%) application (Group I) and 20 eyes were treated using conjunctival autograft (Group II). The mean size of the pterygium was 3.80 mm (range 2.6 to 4.8 mm) in the mitomycin-C group and 3.60 mm (range 2.5 to 4.5 mm) in the conjunctival autograft group. Two (9.52%) eyes treated with intraoperative mitomycin-C had delayed epithelial healing of corneoscleral wound and one (4.76%) eye developed pyogenic granuloma. Three (14.3%) of the 21 eyes in Group I and one (5%) of 20 eyes in Group II had recurrence of pterygium (P = 0.3174). All recurrences occurred in patients below 40 years of age (P = 0.0384).

CONCLUSION

We conclude that conjunctival autograft and intraoperative mitomycin-C are both equally effective adjuncts to primary pterygium surgery on long term follow-up. However, future prospective studies with larger numbers of subjects may be carried out to find out the optimum concentration and duration of intraoperative mitomycin-C application.

Authors+Show Affiliations

Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. eyepgi@ch1.dot.net.inNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10928667

Citation

Sharma, A, et al. "Low-dose Intraoperative mitomycin-C Versus Conjunctival Autograft in Primary Pterygium Surgery: Long Term Follow-up." Ophthalmic Surgery and Lasers, vol. 31, no. 4, 2000, pp. 301-7.
Sharma A, Gupta A, Ram J, et al. Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up. Ophthalmic Surg Lasers. 2000;31(4):301-7.
Sharma, A., Gupta, A., Ram, J., & Gupta, A. (2000). Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up. Ophthalmic Surgery and Lasers, 31(4), 301-7.
Sharma A, et al. Low-dose Intraoperative mitomycin-C Versus Conjunctival Autograft in Primary Pterygium Surgery: Long Term Follow-up. Ophthalmic Surg Lasers. 2000 Jul-Aug;31(4):301-7. PubMed PMID: 10928667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up. AU - Sharma,A, AU - Gupta,A, AU - Ram,J, AU - Gupta,A, PY - 2000/8/6/pubmed PY - 2001/2/28/medline PY - 2000/8/6/entrez SP - 301 EP - 7 JF - Ophthalmic surgery and lasers JO - Ophthalmic Surg Lasers VL - 31 IS - 4 N2 - PURPOSE: To evaluate and compare the long term safety and efficacy of low-dose intraoperative application of mitomycin-C (0.02%) with conjunctival autograft in primary pterygium surgery. PATIENTS AND METHODS: Of 37 consecutive patients 41 eyes with primary pterygium underwent pterygium excision with either intraoperative mitomycin-C (0.02%) (Group I) or conjunctival autografts (Group II) at random. Mitomycin-C (0.2 mg/mL) was applied for 2.5 minutes on the scleral bed under the conjunctiva. Conjunctival autograft was obtained from upper temporal limbus and secured with 10-0 monofilament nylon. The follow-up period ranged from 14 to 54 months (mean 36 months) for mitomycin-C group and 13 to 58 months (mean 38 months) for conjunctival autograft group. RESULTS: Twenty-one eyes underwent pterygium excision with intraoperative mitomycin-C (0.02%) application (Group I) and 20 eyes were treated using conjunctival autograft (Group II). The mean size of the pterygium was 3.80 mm (range 2.6 to 4.8 mm) in the mitomycin-C group and 3.60 mm (range 2.5 to 4.5 mm) in the conjunctival autograft group. Two (9.52%) eyes treated with intraoperative mitomycin-C had delayed epithelial healing of corneoscleral wound and one (4.76%) eye developed pyogenic granuloma. Three (14.3%) of the 21 eyes in Group I and one (5%) of 20 eyes in Group II had recurrence of pterygium (P = 0.3174). All recurrences occurred in patients below 40 years of age (P = 0.0384). CONCLUSION: We conclude that conjunctival autograft and intraoperative mitomycin-C are both equally effective adjuncts to primary pterygium surgery on long term follow-up. However, future prospective studies with larger numbers of subjects may be carried out to find out the optimum concentration and duration of intraoperative mitomycin-C application. SN - 1082-3069 UR - https://www.unboundmedicine.com/medline/citation/10928667/Low_dose_intraoperative_mitomycin_C_versus_conjunctival_autograft_in_primary_pterygium_surgery:_long_term_follow_up_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=10928667.ui DB - PRIME DP - Unbound Medicine ER -